Huangjia Ruangan granules with entecavir for fibrosis regression in Chroinc Hepatitis B: A multicenter, randomized, double-blind, phase II trial
Xiaojun Zhu, Yueqiu Gao(Shanghai University of Traditional Chinese Medicine), Guohong Ge(Jiangsu University), Jinghao Zhang(Fudan University), Shanzhong Tan(Nanjing Second Hospital), Xuehua Sun(Shanghai University of Traditional Chinese Medicine), Zhijia Zhou(Xiamen University), Chunyan Gou(Capital Medical University), Xuan An(Third People 's Hospital of Chongqing), Suthat Liangpunsakul(Indiana University School of Medicine), Jinmo Tang(Fujian University of Traditional Chinese Medicine), Anna Zhang(The University of Texas MD Anderson Cancer Center), Jing Wang(Gansu University of Traditional Chinese Medicine), Man Li(Shanghai University of Traditional Chinese Medicine), Gang Wu(Zhengzhou University), Xinwen Song(First Affiliated Hospital of Xinxiang Medical University), Kewei Sun(First Affiliated Hospital of Hunan University of Traditional Chinese Medicine), Lìyǐng Zhū(Fourth Affiliated Hospital of Harbin Medical University), Yongfang Jiang(Central South University), Hui Lv(Shanghai Public Health Clinical Center)
Cited by 1
Related Papers
Psychological impacts and coping strategies of front-line medical staff during COVID-19 outbreak in Hunan, China
|Medical Science Monitor|2020|784
The Circular RNA Cdr1as Act as an Oncogene in Hepatocellular Carcinoma through Targeting miR-7 Expression
|PLoS ONE|2016|389
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
|New England Journal of Medicine|2022|227